From: medicalxpress.com A team of researchers from Weill Cornell Medicine, the British Columbia Cancer Research Centre and Memorial Sloan Kettering Cancer Center, working with a group from the IMAXT Consortium, has used single-cell sequencing to reveal breast and ovarian cancer-related mutational processes. In their paper published in the journal Nature, the group describes how they conducted single-cell genome sequencing on …
Rare Patient Voice Research opportunity for Ovarian and Fallopian Tube Cancer patients
Details: 60 min web-assisted phone interview Please sign up at the link below to receive an email invite to the survey. Compensation $100 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to …
STILL OPENED: Ancora.ai: Paid Ovarian Cancer Patient Interview
Eligibility Criteria Patients in the US living with ovarian cancer (Stage 3-4) who are willing to discuss their experiences. Study Details Stage 3-4 ovarian cancer patients and their caregivers are invited to participate in a paid study to discuss your experiences with ovarian cancer. Compensation $125 for your time, with additional compensation for an optional pre-work task Link to Sign …
Rare Patient Voice Research opportunity for Ovarian Cancer Patients.
Details: 25 min online online survey Please sign up at the link below to receive an email invite to the survey. Compensation $45 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to …
Ancora.ai: Paid Ovarian Cancer Patient Interview
Eligibility Criteria Patients in the US living with ovarian cancer (Stage 3-4) who are willing to discuss their experiences. Study Details Stage 3-4 ovarian cancer patients and their caregivers are invited to participate in a paid study to discuss your experiences with ovarian cancer. Compensation $125 for your time, with additional compensation for an optional pre-work task Link to Sign …
Rare Patient Voice: Research opportunity for Ovarian Cancer patients
Details: 25 min online survey Please sign up at the link below to receive an email invite to the survey. Compensation $45 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay …
Savvy Cooperative: People who have been diagnosed with Breast, Colon, or Ovarian Cancer
SCREENER Eligibility Criteria: Adult who has been diagnosed with Breast, Colon, or Ovarian Cancer NOTE: Only patients with verified diagnoses will be considered US resident Details: At home opportunity Receive: $110 USD per interview $55 USD per survey Link: https://gigs.savvy.coop/bc-cc-oc/?r=44951 Why Sign Up? Your experiences are so valuable and important to creating better products and services, that companies …
Ancora.ai: New Jersey-Based Patients with cervical, ovarian, or uterine cancer
Eligibility Criteria People living in New Jersey who have had treatment for cervical, ovarian, or uterine cancer in the past 2 years. Study Details 1-hour virtual interview conducted via computer Compensation $150 Link to Sign up https://www.surveymonkey.de/r/NJ_Women Why sign up with Ancora.ai? Participating in research is an incredible way to share your personal opinions and insights to help improve cancer …
FDA Grants Fast-Track Designation to CX-5461 in Treatment of Certain Patients with Breast or Ovarian Cancer
By: Conor Killmurray From: targetedonc.com The FDA has granted a fast-track designation to the G-quadruplex stabilizer CX-5461 for BRCA1/2, PALB2, or HRD mutations in their breast or ovarian cancer. The FDA granted a fast-track designation to the first-in-class G-quadruplex stabilizer CX-5461 (Pindnarulex) for the treatment of patients with BRCA1/2, PALB2, or other homologous recombination deficiency (HRD) mutations in their breast or ovarian …
Rare Patient Voice: Ovarian or Fallopian Tube Cancer Stage III or IV Patients
Study Details: 25 min Online Survey Compensation $45 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! Why …